Does the media prefer MDXG or LMAT?

In the previous week, LeMaitre Vascular had 2 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for LeMaitre Vascular and 2 mentions for MiMedx Group. LeMaitre Vascular's average media sentiment score of 1.24 beat MiMedx Group's score of 0.93 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDXG or BFLY?

In the previous week, Butterfly Network had 6 more articles in the media than MiMedx Group. MarketBeat recorded 8 mentions for Butterfly Network and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.93 beat Butterfly Network's score of 0.29 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, MDXG or NVCR?

MiMedx Group has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $389.42M 1.50 $48.58M $0.20 19.55 NovoCure $655.35M 2.74 -$136.23M -$1.53 N/A

Is MDXG or NVCR more profitable?

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -25.66%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 7.88% 21.03% 15.92% NovoCure -25.66% -50.82% -16.48%

Does the media prefer MDXG or NVCR?

In the previous week, NovoCure had 2 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for NovoCure and 2 mentions for MiMedx Group. NovoCure's average media sentiment score of 0.97 beat MiMedx Group's score of 0.93 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MDXG or EYE?

In the previous week, MiMedx Group and MiMedx Group both had 2 articles in the media. MiMedx Group's average media sentiment score of 0.93 beat National Vision's score of 0.82 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Vision 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MiMedx Group (MDXG) Competitors

$3.91 -0.02 (-0.51%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$3.95 +0.04 (+1.10%)

As of 06/29/2026 07:55 PM Eastern

Compare

MDXG vs. LMAT, BFLY, PLSE, NVCR, and EYE

Should you buy MiMedx Group stock or one of its competitors? MarketBeat compares MiMedx Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiMedx Group include LeMaitre Vascular (LMAT), Butterfly Network (BFLY), Pulse Biosciences (PLSE), NovoCure (NVCR), and National Vision (EYE). These companies are all part of the "medical equipment" industry.

How does MiMedx Group compare to LeMaitre Vascular?

MiMedx Group (NASDAQ:MDXG) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

MiMedx Group has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

MiMedx Group currently has a consensus target price of $8.50, indicating a potential upside of 117.39%. LeMaitre Vascular has a consensus target price of $112.60, indicating a potential upside of 17.29%. Given MiMedx Group's higher possible upside, research analysts clearly believe MiMedx Group is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

LeMaitre Vascular has lower revenue, but higher earnings than MiMedx Group. MiMedx Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.50	$48.58M	$0.20	19.55
LeMaitre Vascular	$249.60M	8.79	$57.73M	$2.71	35.42

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, LeMaitre Vascular had 2 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for LeMaitre Vascular and 2 mentions for MiMedx Group. LeMaitre Vascular's average media sentiment score of 1.24 beat MiMedx Group's score of 0.93 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has a net margin of 24.35% compared to MiMedx Group's net margin of 7.88%. MiMedx Group's return on equity of 21.03% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
LeMaitre Vascular	24.35%	15.36%	9.78%

Summary

LeMaitre Vascular beats MiMedx Group on 11 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Butterfly Network?

MiMedx Group (NASDAQ:MDXG) and Butterfly Network (NYSE:BFLY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 37.9% of Butterfly Network shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 22.0% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MiMedx Group has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market.

In the previous week, Butterfly Network had 6 more articles in the media than MiMedx Group. MarketBeat recorded 8 mentions for Butterfly Network and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.93 beat Butterfly Network's score of 0.29 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 7.88% compared to Butterfly Network's net margin of -73.63%. MiMedx Group's return on equity of 21.03% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Butterfly Network	-73.63%	-34.41%	-23.91%

MiMedx Group has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.50	$48.58M	$0.20	19.55
Butterfly Network	$97.61M	23.35	-$77.06M	-$0.30	N/A

MiMedx Group currently has a consensus target price of $8.50, suggesting a potential upside of 117.39%. Butterfly Network has a consensus target price of $5.56, suggesting a potential downside of 37.85%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities analysts clearly believe MiMedx Group is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

MiMedx Group beats Butterfly Network on 12 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Pulse Biosciences presently has a consensus price target of $30.67, indicating a potential upside of 4.88%. MiMedx Group has a consensus price target of $8.50, indicating a potential upside of 117.39%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,782.00	-$72.78M	-$1.10	N/A
MiMedx Group	$389.42M	1.50	$48.58M	$0.20	19.55

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

In the previous week, MiMedx Group had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 2 mentions for MiMedx Group and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.89 beat MiMedx Group's score of 0.93 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Pulse Biosciences	Very Positive
MiMedx Group	Positive

MiMedx Group has a net margin of 7.88% compared to Pulse Biosciences' net margin of 0.00%. MiMedx Group's return on equity of 21.03% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
MiMedx Group	7.88%	21.03%	15.92%

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 2.5% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

MiMedx Group beats Pulse Biosciences on 12 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to NovoCure?

MiMedx Group (NASDAQ:MDXG) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

MiMedx Group has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

In the previous week, NovoCure had 2 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for NovoCure and 2 mentions for MiMedx Group. NovoCure's average media sentiment score of 0.97 beat MiMedx Group's score of 0.93 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.50	$48.58M	$0.20	19.55
NovoCure	$655.35M	2.74	-$136.23M	-$1.53	N/A

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -25.66%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
NovoCure	-25.66%	-50.82%	-16.48%

MiMedx Group currently has a consensus target price of $8.50, suggesting a potential upside of 117.39%. NovoCure has a consensus target price of $25.67, suggesting a potential upside of 65.81%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts plainly believe MiMedx Group is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 5.5% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MiMedx Group beats NovoCure on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to National Vision?

MiMedx Group (NASDAQ:MDXG) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

MiMedx Group has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, National Vision has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

MiMedx Group has higher earnings, but lower revenue than National Vision. MiMedx Group is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.50	$48.58M	$0.20	19.55
National Vision	$1.99B	0.76	$29.60M	$0.57	32.95

MiMedx Group has a net margin of 7.88% compared to National Vision's net margin of 2.31%. MiMedx Group's return on equity of 21.03% beat National Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
National Vision	2.31%	6.41%	2.81%

79.2% of MiMedx Group shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 2.4% of National Vision shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MiMedx Group currently has a consensus price target of $8.50, indicating a potential upside of 117.39%. National Vision has a consensus price target of $30.08, indicating a potential upside of 60.19%. Given MiMedx Group's stronger consensus rating and higher probable upside, equities analysts plainly believe MiMedx Group is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, MiMedx Group and MiMedx Group both had 2 articles in the media. MiMedx Group's average media sentiment score of 0.93 beat National Vision's score of 0.82 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Vision	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiMedx Group beats National Vision on 11 of the 15 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$585.36M	$3.62B	$6.85B	$12.20B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	19.55	20.93	26.04	24.36
Price / Sales	1.50	343.67	550.39	103.01
Price / Cash	7.09	62.10	29.09	36.93
Price / Book	2.26	8.71	10.98	6.49
Net Income	$48.58M	$23.87M	$3.57B	$336.61M
7 Day Performance	6.54%	4.23%	3.06%	0.90%
1 Month Performance	6.25%	1.71%	0.72%	-0.36%
1 Year Performance	-34.18%	69.92%	36.82%	31.26%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	3.1228 of 5 stars	$3.91 -0.5%	$8.50 +117.4%	-34.2%	$585.36M	$389.42M	19.55	870	News Coverage
LMAT LeMaitre Vascular	4.6539 of 5 stars	$91.67 +3.4%	$112.60 +22.8%	+16.3%	$2.10B	$249.60M	33.89	490	Positive News
BFLY Butterfly Network	1.3126 of 5 stars	$7.80 +7.2%	$5.56 -28.6%	+360.2%	$2.00B	$97.61M	N/A	460	Gap Up
PLSE Pulse Biosciences	2.4323 of 5 stars	$26.13 +1.6%	$30.67 +17.4%	+93.9%	$1.81B	$751K	N/A	140	Gap Up
NVCR NovoCure	3.1869 of 5 stars	$14.14 +3.9%	$26.86 +89.9%	-14.0%	$1.64B	$674.41M	N/A	1,605

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. LMAT, BFLY, PLSE, NVCR, and EYE

How does MiMedx Group compare to LeMaitre Vascular?

Summary

How does MiMedx Group compare to Butterfly Network?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Summary

How does MiMedx Group compare to NovoCure?

Summary

How does MiMedx Group compare to National Vision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. LMAT, BFLY, PLSE, NVCR, and EYE

How does MiMedx Group compare to LeMaitre Vascular?

Which has more volatility & risk, MDXG or LMAT?

Do analysts rate MDXG or LMAT?

Which has preferable earnings and valuation, MDXG or LMAT?

Do insiders and institutionals believe in MDXG or LMAT?

Does the media prefer MDXG or LMAT?

Is MDXG or LMAT more profitable?

Summary

How does MiMedx Group compare to Butterfly Network?

Do institutionals & insiders have more ownership in MDXG or BFLY?

Which has more volatility & risk, MDXG or BFLY?

Does the media prefer MDXG or BFLY?

Is MDXG or BFLY more profitable?

Which has preferable earnings and valuation, MDXG or BFLY?

Do analysts recommend MDXG or BFLY?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Do analysts rate PLSE or MDXG?

Which has preferable valuation & earnings, PLSE or MDXG?

Which has more volatility & risk, PLSE or MDXG?

Does the media refer more to PLSE or MDXG?

Is PLSE or MDXG more profitable?

Do insiders & institutionals have more ownership in PLSE or MDXG?

Summary

How does MiMedx Group compare to NovoCure?

Which has more risk & volatility, MDXG or NVCR?

Does the media prefer MDXG or NVCR?

Which has better earnings & valuation, MDXG or NVCR?

Is MDXG or NVCR more profitable?

Do analysts prefer MDXG or NVCR?

Do insiders and institutionals have more ownership in MDXG or NVCR?

Summary

How does MiMedx Group compare to National Vision?

Which has more risk & volatility, MDXG or EYE?

Which has higher valuation & earnings, MDXG or EYE?

Is MDXG or EYE more profitable?

Do institutionals and insiders hold more shares of MDXG or EYE?

Do analysts recommend MDXG or EYE?

Does the media favor MDXG or EYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools